Regenerative Medicine Utrecht

Jeffrey Beekman, PhD

Professor
Nephrology and Hypertension
UMC Utrecht
jbeekman@umcutrecht.nl

Translational research with stem cells in cystic fibrosis.

Dr. J.M. Beekman (H-index 18) is associate professor and affiliated with the department of pediatric pulmonology and the Regenerative Medicine Center Utrecht. He leads a research group that focuses on the development of individual stem cell based culture technology for personalized therapy of cystic fibrosis (CF), and the study of novel therapeutic options for CF. He has been trained in molecular and cellular biology within an immunological context, and became principle investigator in 2010. He received various prizes including the 2015 Gerd Doring award (European CF society), best translational research prize 2012-2014 (Dutch Respiratory Society) and 2013 best translational article by the Dutch Society for Pediatrics. He was invited speaker at approximately 40 (international) meetings over the last years.

Research

People with cystic fibrosis living healthy lives: I strive to create breakthrough solutions for people with CF by scientific research that focuses on the development of novel diagnostic or therapeutic approaches. This requires a multidisciplinary approach in which basic and clinical research is aligned, and integrated with needs of patients, the private sector and regulatory authorities. We use intestinal stem cell organoids and other primary airway stem cell culture models to predict and understand the individual impact of new CFTR modulating drugs. Close collaborations with the clinical CF center of the UMCU and the Dutch CF patient foundation ensures a continuous focus on translational applications of research findings. Currently, I am particularly proud of leading a team effort that led to personalized treatment of CF within 4 years after the initial discovery.

Active projects:

2015 – 2018 ZonMW TOP 40-00812-98-14103: Cure for a genetic disease? Targeting the right drug to the right patient using intestinal stem cell cultures in Cystic Fibrosis.
Goal: To develop a predictive model for individual therapy using intestinal organoids and define mechanisms of optimal compound combinations for CFTR repair.

2015 – 2017 European H2020 program (SEP-210176765): Clinical proof of concept for a RNA-targeting Oligonucleotide for a Cystic Fibrosis-F508del medication.
Goal: perform biomarker analysis for a first in human trial for novel RNA oligo based RNA editing technology

2014 – 2016 ZonMW 40-41200-98-9216 Personalizing B2-adrenergic receptor agonist therapy for people with CF using in vitro cultures of intestinal organoids.
Goal: demonstrate proof-of-concept for using organoids as screening platform to repurpose existing drugs for select CF subsets

2014 – 2016 ZonMW 40-41200-98-9227 CFTR repair by genistein, curcumin and VX-770 (Ivacaftor) in cystic fibrosis patients carrying the S1251N channel gating mutation.
Goal: demonstrate proof-of-concept for using organoids as screening platform to repurpose food components as potentiators for CF S1251N subsets

Selected literature

Pubmed search: Beekman JM

  1. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Johanna F. Dekkers, Gitte Berkers, Evelien Kruisselbrink, Annelotte Vonk, Hugo R. de Jonge, Hettie M. Janssens, Inez Bronsveld, Eduard A. van de Graaf, Edward E. S. Nieuwenhuis, Roderick H. J. Houwen, Frank P. Vleggaar, Johanna C. Escher, Yolanda B. de Rijke, Christof J. Majoor, Harry G. M. Heijerman, Karin M. de Winter-de Groot, Hans Clevers, Cornelis K. van der Ent and Jeffrey M. Beekman. Science Translational Medicine 2016, 8 (344), 344ra84.
  2. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Johanna F. Dekkers, Ricardo A. Gogorza Gondra, Evelien Kruisselbrink, Annelotte M. Vonk, Hettie M. Janssens, Karin M. de Winter-de Groot, Cornelis K. van der Ent, Jeffrey M. Beekman. European Respiratory Journal 2016 Apr 21. doi: 10.1183/13993003.01192-2015.
  3. Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EE, Beekman JM, Clevers H. Cell Stem Cell. 2013 Dec 5;13(6):653-8.
  4. A functional CFTR assay using primary cystic fibrosis intestinal organoids. J.F. Dekkers, C.L. Wiegerinck, H.R. de Jonge, I. Bronsveld, H.M. Janssens, K.M de Winter-de Groot, A.M. Brandsma, N.W.M. de Jong, M.J.C. Bijvelds, B.J. Scholte, E.E.S Nieuwenhuis, S. van den Brink, H. Clevers, C.K. van der Ent, S. Middendorp, J.M. Beekman. Nat Med. 2013 Jul;19(7):939-45
  5. Mechanism-based corrector combination synergistically restores ΔF508- CFTR folding and function in cystic fibrosis. Tsukasa Okiyoneda, Guido Veit, Johanna F. Dekkers, Haijin Xu, Ariel Roldan, Miklos Bagdany, A. S. Verkman, Mark Kurth, Agnes Simon, Tamas Hegedus,
    Jeffrey M. Beekman, Gergely L. Lukacs. Nat Chem Biol. 2013 Jul;9(7):444-54

Contact

Mailing address for correspondence

J.M. Beekman
University Medical Center Utrecht, Wilhelmina Children’s hospital
Room number KH.01.419.0
Postbus 85090
3508 AB Utrecht
The Netherlands
E: jbeekman@umcutrecht.nl
T: +31 88 755 3201

Mailing address for packages
UMC Utrecht
(location Hubrecht Institute, reception)
Tav RMCU, Evelien Kruisselbrink (T: 06-20114848)
Uppsalalaan 8
3584 CT Utrecht
Internal box: 4th floor, North, green area.